Previous studies have revealed that the liver is the main target organ of deposition for engineered nanoparticles. The hepatotoxicity of silver nanoparticles (AgNPs), the widely used antimicrobial nanoparticles, has been of great interest. However, little is known about the regulatory mechanism of the mitochondria in AgNP-induced hepatotoxicity. In the present study, we found that AgNPs, rather than silver ions, induced mitochondrial dynamics disorders, oxidative stress, and mitochondria-dependent hepatocyte apoptosis in mice. Using human hepatocellular carcinoma (HepG2) cells, we confirmed that the interaction between dynamin-related protein 1 (DRP1)-dependent mitochondrial fission and oxidative stress promoted mitochondrial damage and mitochondria-dependent apoptosis induced by AgNPs, as determined by the elimination of DRP1 or addition of N-acetylcysteine (NAC). Interestingly, the crosstalk between DRP1-dependent mitochondrial fission and oxidative stress also activated mitophagy and autophagy flux blocking. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) gene silencing contributed to the aggravation of mitochondrial damage, oxidative stress, and apoptosis. These results revealed that the interplay between mitochondrial fission and oxidative stress induced mitophagy defects and triggered AgNP-induced mitochondria-dependent apoptosis in liver cells both in vivo and in vitro. Our findings provide a perspective for the mechanism of hepatotoxicity induced by exposure to metal NPs.
As global population aging intensifies, the incidence of central nervous system (CNS) disorders escalates, while obstacles like the blood-brain barrier (BBB) impede effective medication delivery. Plant-derived exosome-like nanovesicles (PELNVs), as innovative therapeutic carrier, have garnered significant interest in their capacity to transport medications across the BBB. A substantial emphasis is focused on the diverse therapeutic potential of PELNVs, underscoring their direct neuroprotective, antiinflammatory, and antioxidant properties, along with their nascent function in altering the gut-brain axis to indirectly mitigate neuroinflammation. We subsequently compile information elucidating the processes by which PELNVs transport therapeutic cargo to the brain, including receptor-mediated transcytosis and their tailored targeting techniques. Ultimately, we address the prevailing difficulties. In summary, PELNVs embody a revolutionary, multi-faceted strategy with significant promise to address the persistent challenges in CNS medication delivery and treatment.